share_log

Independent Director Deborah Autor Sold A Bunch Of Shares In Amneal Pharmaceuticals

Independent Director Deborah Autor Sold A Bunch Of Shares In Amneal Pharmaceuticals

獨立董事黛博拉·奧特出售了Amneal Pharmicals的大量股票
Simply Wall St ·  05/22 18:08

We'd be surprised if Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) shareholders haven't noticed that the Independent Director, Deborah Autor, recently sold US$256k worth of stock at US$6.74 per share. The eyebrow raising move amounted to a reduction of 29% in their holding.

如果Amneal Pharmicals, Inc.(納斯達克股票代碼:AMRX)的股東沒有注意到獨立董事黛博拉·奧特最近以每股6.74美元的價格出售了價值25.6萬美元的股票,我們會感到驚訝。此次舉措使他們的持股量減少了29%。

Amneal Pharmaceuticals Insider Transactions Over The Last Year

去年的Amneal Pharmicals內幕交易

Notably, that recent sale by Deborah Autor is the biggest insider sale of Amneal Pharmaceuticals shares that we've seen in the last year. So what is clear is that an insider saw fit to sell at around the current price of US$6.69. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

值得注意的是,黛博拉·奧特最近的出售是我們去年對Amneal Pharmicals股票的最大一次內幕出售。因此,顯而易見的是,一位內部人士認爲以當前6.69美元左右的價格賣出是合適的。我們通常不喜歡看到內幕銷售,但是銷售價格越低,我們就越擔心。我們注意到,此次銷售的價格約爲當前價格,因此儘管這不是一個好兆頭,但這並不是一個主要問題。

In the last year Amneal Pharmaceuticals insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

去年,Amneal Pharmicals內部人士沒有購買任何公司股票。下圖顯示了去年的內幕交易(公司和個人)。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!

insider-trading-volume
NasdaqGS:AMRX Insider Trading Volume May 22nd 2024
納斯達克股票代碼:AMRX 內幕交易量 2024 年 5 月 22 日

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

如果你喜歡買入內部人士正在買入的股票,而不是賣出,那麼你可能會喜歡這份免費的公司名單。(提示:它們中的大多數都在雷達下飛行)。

Insider Ownership Of Amneal Pharmaceuticals

Amneal製藥的內部所有權

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Amneal Pharmaceuticals insiders own about US$1.1b worth of shares (which is 53% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

我喜歡看看內部人士在一家公司擁有多少股票,以幫助我了解他們與內部人士的看法。較高的內部所有權通常會使公司領導層更加關注股東的利益。Amneal Pharmicals內部人士擁有價值約11億美元的股份(佔該公司的53%)。我喜歡看到這種程度的內部所有權,因爲它增加了管理層考慮股東最大利益的機會。

So What Does This Data Suggest About Amneal Pharmaceuticals Insiders?

那麼這些數據對Amneal Pharmicals Insiders有什麼啓示呢

An insider sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example, Amneal Pharmaceuticals has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about.

一位內部人士最近出售了股票,但他們一直沒有買入。在過去的一年裏,沒有任何能讓我們感到安慰的購買。儘管內部人士確實擁有該公司的大量股份(這很好),但我們對他們交易的分析並不能使我們對公司充滿信心。因此,雖然了解內部人士在買入或賣出方面的所作所爲很有幫助,但了解特定公司面臨的風險也很有幫助。例如,Amneal Pharmicals有3個警告信號(其中一個不容忽視),我們認爲你應該知道。

But note: Amneal Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但請注意:Amneal Pharmicals可能不是最好的買入股票。因此,來看看這份投資回報率高、債務低的有趣公司的免費清單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論